The contact activation and kallikrein/kinin systems: Pathophysiologic and physiologic activities

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 1, 2016, Pages 28-39

  Schmaier, A H ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Bradykinin; Contact activation; Factor XII; Kallikrein kinin system; Kininogen; Prekallikrein

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; PREKALLIKREIN; PROLINE CARBOXYPEPTIDASE; BRADYKININ; BRADYKININ RECEPTOR; PLASMA KALLIKREIN;

ARTERY THROMBOSIS; BIOCHEMISTRY; BLEEDING; BLOOD CLOTTING; COMPLEMENT SYSTEM; CONTACT ACTIVATION SYSTEM; CYTOLOGY; DEFENSE MECHANISM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VEIN THROMBOSIS; ANIMAL; BLOOD CLOTTING DISORDER; DEFICIENCY; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; MOUSE; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BRADYKININ; FACTOR XII; FACTOR XIIA; HEMOSTASIS; HOMEOSTASIS; HUMANS; INFLAMMATION; KALLIKREIN-KININ SYSTEM; KININOGEN, HIGH-MOLECULAR-WEIGHT; MICE; PLASMA KALLIKREIN; PREKALLIKREIN; RECEPTORS, BRADYKININ; THROMBOSIS;

EID: 84954481747     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13194     Document Type: Review

References (100)

1. Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases: a critical role of kallikrein. J Exp Med 1973; 138: 1564-84.
2. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-9.
3. Pickering JW, Hewitt JA. Studies of the coagulation of the blood: part I. Some physio-chemical aspects of coagulation. Biochem J 1921; 15: 710-24.
4. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
5. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its functions as a biochemical amplifier. Nature 1964; 202: 498-9.
6. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
7. Merkoulov S, Komar AA, Schmaier AH, Barnes E, Zhou Y, Lu X, Iwaki T, Castellino FJ, Lou G, McCrae KR. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-81.
8. -/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1 and KLF4 and decreased tissue factor. Blood 2015; 125: 710-9.
9. Inoue Y, Peter LL, Yim SH, Inoue J, Gonzalez FJ. Role of hepatocyte nuclear factor 4 alpha in control of blood coagulation factor gene expression. J Mol Med 2006; 84: 334-44.
10. Stavrou E, Schmaier AH. Factor XII: what does its contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125: 210-5.
11. Citarella F, Fedele G, Roem D, Fantoni A, Hack CE. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood 1998; 92: 4198-206.
12. Cichon S, Martin L, Hennies HC, Mueller F, van Driessche K, Karpushova A, Stevens W, Colomb R, Renne T, Drouet C, Bork K, Noethen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-104.
13. Mahdi F, Shariat-Madar Z, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-96.
14. Wujak L, Didiasova M, Zakrzewicz D, Frey H, Schasfer L, Wygrecka M. Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surface. J Biol Chem 2015; 290: 7027-39.
15. LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115: 5111-20.
16. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 2007; 5: 2323-9.
17. Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12: 1513-22.
18. Renné T, Dedio J, Meijers JC, Chung D, Muller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999; 274: 25777-84.
19. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-28.
20. Zhao Y, Qui Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH. Assembly and activation of the HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 2001; 280: H1821-9.
21. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-61.
22. Wang J, Matafonov A, Madkhali H, Mahdi F, Watson D, Schmaier AH, Gailani D, Shariat-Madar Z. Mapping prolylcarboxypeptidase interaction sites on plasma prekallikrein. Curr Mol Med 2014; 14: 1173-85.
23. Soisson SM, Patel SB, Abeywickrema PD, Byrne NJ, Diehl RE, Hall DL, Ford RE, Reid JC, Rickert KW, Shipman JM, Sharma S, Lumb KJ. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct Biol 2010; 10: 16.
24. Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP. Factor XII-independent activation of the bradykinin-forming cascade: implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol 2013; 132: 470-5.
25. Abildgaard CF, Harrison J. Fletcher factor deficiency: family study and detection. Blood 1974; 43: 641-4.
26. Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH; the DCCT/EDIC Study Group. Plasma prekallikrein. A risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 2003; 52: 1215-21.
27. Phipps JA, Clemont AC, Sinha S, Chilcote TJ, Bursell S-E, Feener EP. Pasma kallikrein mediates angiotensin II type 1 receptor-stimulated retainal vascular permeability. Hypertension 2009; 53: 175-81.
28. Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S, Feenre EP. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011; 60: 1590-8.
29. Colman RW, Schmaier AH. Contact activation: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
30. Bradford HN, Schmaier AH, Colman RW. Kinetics of inhibition of platelet calpain II by human kininogens. Biochem J 1990; 270: 83-90.
31. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-10.
32. Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 1987; 262: 1405-11.
33. Hasan AAK, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH. High molecular weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelial cells. Blood 1995; 85: 3134-43.
34. Fujikawa K, Chung DW, Hendrickson LE, Davie EW. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-24.
35. Chung DW, Fujikawa K, McMullen BA, Davie EW. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-7.
36. Ben Nasr AB, Herwald H, Müller-Esterl W, Björck L. Human kininogens interact with M protein, a bacterial surface protein and virulence determinant. Biochem J 1995; 305: 173-80.
37. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Müller-Esterl W. Identification of an endothelial cell binding site on kininogens' domain D3. J Biol Chem 1995; 270: 14634-42.
38. Hasan AAK, Cines DB, Zhang J, Schmaier AH. The C-terminus of bradykinin and N-terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 1994; 269: 31822-30.
39. Mahdi F, Shariat-Madar Z, Schmaier AH. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J Biol Chem 2003; 278: 43983-90.
40. Renné T, Dedio J, David G, Müller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-96.
41. Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH. Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor. J Biol Chem 2004; 279: 16621-8.
42. LaRusch GA, Merkulova A, Mahdi F, Shariat-Madar Z, Sitrin RG, Cines DB, Schmaier AH. uPAR's domain 2 regulates single chain urokinase-mediated angiogenesis through β1 integrin and VEGFR2. Am J Physiol Heart Circ Physiol 2013; 305: H305-20.
43. Chavakis T, Kanse SM, Lupu F, Hammes HP, Müller-Esterl W, Pixley RA, Colman RW, Preissner KT. Different mechanism define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 2000; 96: 514-22.
44. Chavakis T, Kanse SM, Pixley RA, May AE, Isordia-Salas I, Colman RW, Preissner KT. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J 2001; 15: 2365-76.
45. Daniel J-M, Reich F, Dutzman J, Weisheit S, Teske R, Gunduz D, Bauersachs J, Preissner KT, Sedding DG. Cleaved high-molecular-weight kinnogen inhibits neointima formation following vascular injury. Thromb Haemost 2015; 114: 603-13.
46. Rebuck JW. The skin window as a monitor of leukocytic functions in contact activation factor deficiencies in man. Am J Clin Pathol 1983; 79: 405-13.
47. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
48. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980; 18: 787-95.
49. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
50. Schmaier AH, Colman RW, Silverberg M, Kaplan AP. The contact activation system: surface mediated defense reactions. In: Colman RW, ed. Hemostasis, 2nd edn. Philadelphia, PA: Lippincott, 1987: 18-36.
51. Vogler EA, Siedlecki CA. Contact activation of blood-plasma coagulation. Biomaterials 2009; 30: 1857-69.
52. Golas A, Yeh CH, Pitakjakpipop H, Siedlecki CA, Vogler EA. A comparison of blood factor XII autoactivation in buffer, protein cocktail, serum, and plasma solutions. Biomaterials 2013; 34: 607-20.
53. Silverberg M, Dunn JT, Garen L, Kaplan AP. Auto-activation of human Hageman-factor - demonstration utilizing a synthetic substrate. J Biol Chem 1980; 255: 7281-6.
54. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 1992; 267: 19691-7.
55. Wang J, Even MA, Chen X, Schmaier AH, Waite JH, Chen Z. Detection of amide I signals of interfacial proteins in situ using SFG. J Am Chem Soc 2003; 125: 9914-5.
56. Langdell RD, Wagner RH, Brinkhouse KM. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
57. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
58. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-9.
59. Wilner GD, Nossel HI, LeRoy EC. Activation of Hageman factor by collagen. J Clin Invest 1968; 47: 2608-15.
60. Zacharski IR, Rosenstein R. Failure of collagen to activate factor XII. Thromb Res 1975; 7: 929-33.
61. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-35.
62. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-93.
63. Mass C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-18.
64. Zamolodchikov D, Chen Z-L, Conti BA, Renné T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci USA 2015; 112: 4068-73.
65. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphates modulate blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-8.
66. van der Meijden PEJ, Munnix ICA, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP, Renné T, Heemskerk JW. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 115: 881-90.
67. Rojkjaer R, Hasan AAK, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
68. Puy C, Tucker EI, Wong ZC, Gailani D, Smith SA, Choi SH, Morrissey JH, Gruber A, McCarty OJT. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost 2013; 11: 1341-52.
69. Frick I-M, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98: 497-502.
70. Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during Hantavirus infection involves factor XII-dependent increased activation o thfe kallikrein-kinin system. PLoS Pathog 2013; 9: e1003470.
71. Scharfstein J, Andrade D, Svensjo E, Oliveire A, Nascimento CR. The kallikrein-kinin system in experimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi. Front Immunol 2013; 3: 396.
72. Cotrin SS, Gouvea IE, Melo PMS, Bagnaresi P, Assis DM, Araujo MS, Juliano MA, Gazarini ML, Rosenthal PJ, Juliano L, Carmona AK. Substrate specificity studies of the cysteine peptidases falcipain-2 and falcipain-3 from Plasmodium falciparum and demonstration of their kininogenase activity. Mol Biochem Parasitol 2013; 187: 111-6.
73. Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamsa A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broome M, Pragst I, Dickneite G, Wilson MJ, Nasj AD, Panousis C, Renné T. A factor XII inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
74. Schmaier AH. Extracorporeal circulation without bleeding. Sci Transl Med 2014; 6: 222fs7.
75. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxiparin, and heparin in vitro and in vivo. Blood 2011; 118: 6667-74.
76. Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it. J Thromb Haemost 2015; 13(Suppl. 1): S72-81.
77. Prasad JM, Gorkun OV, Raghu H, Thornton S, Mullins ES, Palumbo JS, Ko Y-P, Hook M, Coughlin SR, Degen JL, Flick MJ. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. Blood 2015; 126: 2047-58.
78. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wuillemn WA, Nilsson G, Renné T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-68.
79. Pixley RA, Schmaier AH, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by C1 inhibitor. Arch Biochem Biophys 1987; 256: 490-8.
80. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 2010; 56: 384-90.
81. Zhu L, Carretero OA, Xu J, Wang L, Harding P, Rhaleb NE, Yang JJ, Sumners C, Yang XP. Angiotensin II type 2 receptor-stimulated activation of plasma prekallikrein and bradykinin release: role of SHP-1. Am J Physiol Heart Circ Physiol 2012; 302: H2553-9.
82. Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. Pediatr Allergey Immunol Pulmonol 2014; 27: 159-63.
83. Björkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schönig K, Nöthen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, Renné T. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132-46.
84. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ, Curd JG, Colman RW. Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308: 1050-3.
85. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 2015; 70: 506-13.
86. Madsen DE, Sidelmann JJ, Biltoft D, Gram J, Hansen S. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: implication for a role in hereditary angioedema. Biochim Biophys Acta 2015; 1850: 1336-42.
87. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, Finlayson JS. Hypotension associated with prekallikrein activator (Hageman-factor fragment) in plasma protein fraction. N Engl J Med 1978; 299: 66-70.
88. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-67.
89. Corbier A, Le Berre N, Rampe D, Meng H, Lorenz M, Vicat P, Potdevin S, Doubovetzky M. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat. Toxicol Sci 2011; 121: 417-27.
90. Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, Ronquist G, Renné T. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126: 1379-89.
91. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
92. Konings J, Hoving LR, Ariëns RS, Hethershaw EL, Ninivaggi M, Hardy LJ, de Laat B, ten Cate H, Philippou H, Govers-Riemslag JW. The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thromb Res 2015; 136: 474-80.
93. Langhauser F, Göb E, Kraft P, Geis C, Schmitt J, Brede M, Göbel K, Helluy X, Pham M, Bendszus M, Jakob P, Stoll G, Meuth SG, Nieswandt B, McCrae KR, Kleinschnitz C. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012; 120: 4082-92.
94. Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP, Seiffert D. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-50.
95. Barbieri SS, Amadio P, Gianellini S, Tarantino E, Zacchi E, Veglia F, Howe LR, Weksler BB, Mussoni L, Tremoli E. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 2012; 126: 1373-84.
96. Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, Krijano Y, Murphey LJ, Jaffa AA, Schmaier AH. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 2006; 108: 192-9.
97. -/- mice by increasing NO and prostacyclin to reduce platelet spreading and GPVI activation. Blood 2013; 121: 3023-32.
98. Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman M, Jacobs G, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D'Alecy LG, Schmaier AH. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011; 117: 3929-37.
99. Adams GN, Stavrou EX, Fang C, Merkulova A, Alaiti MA, Nakajima K, Morooka T, Merkulov S, LaRusch GA, Simon DI, Jain MK, Schmaier AH. Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood 2013; 122: 1522-31.
100. Grobe N, Weir NW, Leiva O, Ong FS, Bernstein KE, Schmaier AH, Morris M, Elased KM. Novel proteomic approaches identify prolyl carboxypeptidase as alternative enzyme for renal angiotensin II processing. Am J Physiol Cell Physiol 2013; 304: C945-53.